With the development of next-generation sequencing (NGS), a variety of co-mutations have been found in NSCLC patients with EGFR mutations, among which TP53 mutations are the most common co-mutation type, with an incidence rate as high as 17.3–72.5% (9, 10). Here, EGFR is linked to non-small cell lung carcinoma.